We next integrated the GTEx database and TCGA database and assessed the SPARCL1 transcriptional level in 11 other cancers, including adrenocortical carcinoma (ACC), lymphoid neoplasm diffuse large B-cell lymphoma (DLBC), acute myeloid leukemia (LAML), brain lower-grade glioma (LGG), ovarian serous cystadenocarcinoma (OV), sarcoma (SARC), skin cutaneous melanoma (SKCM), testicular germ cell tumors (TGCT), thymoma (THYM), uterine carcinosarcoma (UCS), and uveal melanoma (UVM). Here, SPARCL1 is linked to sarcoma.